Ocugen
Ocugen, Inc. is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, dedicated to discovering, developing, and commercializing innovative therapies aimed at curing blinding diseases. The company's pipeline includes several promising product candidates, such as OCU200, a novel fusion protein in preclinical development for treating wet age-related macular degeneration (AMD), diabetic retinopathy, and diabetic macular edema. Additionally, Ocugen is developing OCU400 for retinitis pigmentosa, a rare genetic disorder, and OCU410 for dry AMD. The company utilizes its Modifier Gene Therapy Platform to address unmet medical needs in the field of retinal diseases, including inherited conditions and multifactorial diseases. Ocugen has also established a strategic partnership with CanSino Biologics Inc. for the co-development and manufacturing of gene therapies.
Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Our regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Our first investigational product candidate, NeoCart®, leverages our platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.